Literature DB >> 2928556

Radiation dose assessments in radioiodine (131I) therapy. 1. The necessity for in vivo quantitation and dosimetry in the treatment of carcinoma of the thyroid.

T Schlesinger1, M A Flower, V R McCready.   

Abstract

In order to destroy thyroid cancer metastases by radioiodine an average tissue dose of 80-300 Gy is needed. Such high doses can be expected, following the administration of the conventional 5.5 GBq of 131I, only if both the percentage uptake per gram in the target tissue and the effective half life of the radioiodine in it are higher than well-defined threshold values, and if every dimension of the tissue exceeds several millimeters. The fulfillment of such favourable conditions in actual clinical cases can only be confirmed by in vivo quantitation of the absorbed dose achieved as a result of the administration of radioiodine.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2928556     DOI: 10.1016/0167-8140(89)90006-6

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  5 in total

1.  A different approach to the use of unsealed radionuclides for cancer therapy.

Authors:  V R McCready
Journal:  Eur J Nucl Med       Date:  1995-01

Review 2.  Radioiodine-remnant ablation in low-risk differentiated thyroid cancer: pros.

Authors:  Kenneth B Ain
Journal:  Endocrine       Date:  2015-06-25       Impact factor: 3.633

3.  In vitro and in vivo characterizations of established human follicular carcinoma cell line derived from thyroid cancer: a novel model for well-differentiated thyroid malignant tumor.

Authors:  T Tsuda
Journal:  Ann Nucl Med       Date:  1992-08       Impact factor: 2.668

4.  Tumour dosimetry and response in patients with metastatic differentiated thyroid cancer using recombinant human thyrotropin before radioiodine therapy.

Authors:  Bart de Keizer; Boudewijn Brans; Anne Hoekstra; Pierre M J Zelissen; Hans P F Koppeschaar; Cees J M Lips; Peter P van Rijk; Rudi A Dierckx; John M H de Klerk
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-12-19       Impact factor: 9.236

5.  Recombinant human thyroid stimulating hormone in 2008: focus on thyroid cancer management.

Authors:  Ann Gramza; Kathryn G Schuff
Journal:  Onco Targets Ther       Date:  2009-01-01       Impact factor: 4.147

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.